Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant.
Mark van Barele, Delal Akdeniz,Bernadette A M Heemskerk-Gerritsen,Nadine Andrieu,Catherine Noguès,Christi J van Asperen,Marijke Wevers,Margreet G E M Ausems,Geertruida H de Bock, Charlotte J Dommering, Encarnacion B Gómez-García,Flora E van Leeuwen,Thea M Mooij,Douglas F Easton,Antonis C Antoniou,D Gareth Evans,Louise Izatt,Marc Tischkowitz, Debra Frost,Carole Brewer,Edit Olah,Jacques Simard,Christian F Singer,Mads Thomassen,Karin Kast,Kerstin Rhiem,Christoph Engel,Miguel de la Hoya,Lenka Foretová,Anna Jakubowska,Agnes Jager,Margriet G A Sattler,Marjanka K Schmidt,Maartje J Hooning Journal of the National Cancer Institute（2023）
摘要
Radiotherapy regimens minimizing contralateral breast dose should be considered in gBRCA1/2 pathogenic variant carriers.
更多查看译文
AI 理解论文
溯源树
样例
